key: cord-0982242-uac76hnr
authors: Erkayman, Merve H.; Bilen, Handan
title: Clearance of longstanding treatment‐resistant warts during COVID‐19 in a transplant recipient
date: 2021-02-16
journal: Transpl Infect Dis
DOI: 10.1111/tid.13572
sha: e9283c9f54e910683b1fb3cc06bfe1b41d991e2c
doc_id: 982242
cord_uid: uac76hnr

Human papillomavirus (HPV), a DNA virus, infects basal keratinocytes and causes common warts and as well as malignancies of skin and mucous membranes. Although many treatment options are available, persistent HPV infections are common among transplant recipients. Herein, we present a patient with a 15‐year history of treatment‐resistant warts that regressed during COVID‐19 (Coronavirus disease 2019) treatment.

A 49-year-old man, who had a history of renal transplantation 18 years ago, was admitted to our clinic with numerous treatmentresistant warts that started 3 years after the transplantation. Clinical examination revealed numerous verrucous papules and nodules on his hands and fingers ( Figure 1A ). He was on methylprednisolone, mycophenolate mofetil, and cyclosporine as immunosuppressive therapy. During several years of follow-up, many treatment modalities had been used, including cryotherapy, electrocautery, imiquimod, trichloroacetic acid, and acitretin without any satisfactory response.

During the SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) pandemic, the patient could not be followed clinically. In September 2020, he presented to the emergency department with a cough and shortness of breath. SARS-COV-2 PCR was negative but multiple focal ground-glass opacities suggesting viral pneumonia due to COVID-19 were detected on chest tomography. After 1 week of treatment at home, he had needed hospitalization due to hypoxia requiring nasal oxygen support. Laboratory investigations revealed elevated levels of C-reactive protein (95.96 mg/L), ferritin (579.5 ng/ mL), creatinine (1.78 mg/dL), lymphopaenia (0.53 10 3 /µL), and normal levels of d-dimer. Favipiravir, azithromycin, low molecular-weight heparin, and dexamethasone were commenced and methylprednisolone was discontinued. During COVID-19 treatment, the patient noticed that some verrucae had shrunk and disappeared without any specific treatment for them. He stated that the improvement of verrucae has continued for 2-3 weeks. The patient denied any newly developed skin lesion or rash during COVID-19. Physical examination showed a significant decrease in the number and size of the lesions on his hands compared to the previous ones ( Figure 1B ). Two months later, partial regrowth of the warts was detected ( Figure 1C ). five main groups as maculopapular exanthema, urticarial eruptions, vasculitis, vesicular eruptions, and chilblain-like lesions. 5 Cutaneous involvement is related to the interaction between cellular and humoral immune response. 4 Proposed underlying pathogenic mechanisms for skin involvement of COVID-19 are summarized in Table 1 . 3, 4 As far as we know, this is the first report about a dramatic regression of treatment-resistant warts in a patient with COVID-19.

Although we cannot clearly explain the underlying mechanism, we will focus on three possibilities:

1. Antiviral effect of favipiravir: Favipiravir, an RNA-dependent RNA polymerase inhibitor, is widely used in the treatment of COVID-19. 6 Although there is no information in the literature re- SARS-CoV-2 induces both innate and adaptive immune responses. It is suggested that type 1 interferons and activation of both CD4+ Th1 and CD8+ cytotoxic T lymphocytes provide viral clearance in patients with COVID-19. 3, 7 When viral spread could not be controlled, cytokine storm characterized by increased levels of IL-1, IL-6, IL-12, and TNFα was associated with many organ damages in COVID-19. 3 Tissue damage in verrucae by the same mechanism is a possibility.

The hypoxic state of the patient due to COVID-19 may also have an impact on the regression of warts. Besides, regrowth of warts 3 months after COVID 19 also suggests an improvement may be associated with COVID-19.

Although spontaneous regression cannot be ruled out definitely, we can say that this is unlikely, given the 15-year history of the treatment-resistant disease course.

In conclusion, we observed a dramatic regression of longstanding treatment-resistant warts in a transplant recipient during the treatment of COVID-19. Certainly, this temporal association does not mean that the regression of warts is strictly COVID-19 related.

Further studies involving clinical follow-up of patients with verrucae during and after SARS-CoV-2 infection may shed light on this issue.

No conflict of interest.

Merve H. Erkayman https://orcid.org/0000-0002-9230-2190

Natural course of cutaneous warts among primary school children: a prospective cohort study

Benign human papillomavirus infection in renal transplant recipients

SARS-CoV-2, COVID-19, skin and immunology -What do we know so far?

Unraveling the mystery of Covid-19 cytokine storm: from skin to organ systems

Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases

Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase

Coronavirus infections and immune responses